Procter & Gamble Health Limited (PGHL) fair value: what the stock is really worth
We calculate from audited financials what Procter & Gamble Health Limited is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Procter & Gamble Health Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
60‑month range ₹3,484 – ₹6,919 · fair‑value band ₹3,280 – ₹7,064 · the ₹5,412 price screens above the ₹5,073 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 13, 2026.
Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemical products in India and internationally. The company offers over-the-counter products, vitamins, minerals, and supplements. It offers its products under the Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas brands.
Show more
Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemical products in India and internationally. The company offers over-the-counter products, vitamins, minerals, and supplements. It offers its products under the Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas brands. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019. Procter & Gamble Health Limited was incorporated in 1967 and is headquartered in Mumbai, India. Procter & Gamble Health Limited is a subsidiary of Procter & Gamble Overseas India B.V.
Stock analysis
Procter & Gamble Health Limited (PGHL) currently trades at ₹5,412, while our model-based Fair Value estimate is ₹5,073, implying the stock looks roughly 6.7% fairly valued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹3,937 per share, and 0 of the 26 models we run sit above the ₹5,412 price.
Bear case: the Economic Profit group reads lowest at ₹1,339, and 26 of the 26 models stay below the price. Evidence for this calculation is medium.
Scenario range: ₹3,280 (bear) to ₹7,064 (bull), the price of ₹5,412 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 93/100 (high quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Procter & Gamble Health Limited reported revenue of ₹14.1B in FY2025 versus ₹11.1B in FY2021, a compound +6.0%/yr. Reported net income was ₹3.3B in FY2025, compounding +14.2%/yr from FY2021.
Key figures
Market cap ₹106B (≈ $1.1B) · P/E ratio 27.5 · P/S ratio 6.37 · EPS (TTM) ₹197.12 · Dividend yield 3.8% · Net margin 23.2% · Return on equity 61.6% · Return on assets (EBIT) 60.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 19% below its 52-week high and 15% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −17% fair-value upside, at −6%, PGHL screens cheaper than that median.
Fair Value models
Bear ₹3,280Fair Value ₹5,073Bull ₹7,064
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.76/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+15.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.0%
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+10.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+6.7%
Dividend (yield on the price)3.8%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.11% vs 20%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.21% → 31%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+22.0%
Yearly growth needed for the next five years to justify today's price.
Compare Procter & Gamble Health Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 612 stocks
Beats the industry median on 10/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score93 · Top 25%
Fair Value upside−10% · Above median
Profitability
Return on equity (TTM)62% · Top 25%
Return on assets33% · Top 25%
Net margin (TTM)23% · Top 25%
Operating margin (TTM)35% · Top 25%
Growth and dividend
Revenue growth19% · Top 25%
Dividend yield (TTM)3.8% · Top 25%
Balance sheet
Debt / equity0.01× · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Procter & Gamble Health Limited Fair Value". https://www.fairvalue-calculator.com/stock/PGHL
Frequently asked questions
Is Procter & Gamble Health Limited (PGHL) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of ₹5,073 versus a price of ₹5,412, about −6% upside (fairly valued).
What is the fair value of PGHL?
Our model-based fair value for Procter & Gamble Health Limited is ₹5,073 (as of Sep 13, 2026), built from audited fundamentals. The current price: ₹5,412.
What is the quality score of PGHL?
Procter & Gamble Health Limited has a Quality Score of 93/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Procter & Gamble Health Limited (PGHL)?
Our model-based price target is the fair value of ₹5,073 (as of Sep 13, 2026) from 26 valuation models. Cautious scenario ₹3,280, optimistic scenario ₹7,064. It is a calculation from audited fundamentals, not an analyst target.
What is the Procter & Gamble Health Limited stock forecast for 2026?
Our models put fair value at ₹5,073, about −6% upside versus a price of ₹5,412 (fairly valued). Cautious scenario ₹3,280, optimistic scenario ₹7,064. The calculation is refreshed regularly with new filings.
What is the revenue of Procter & Gamble Health Limited (PGHL)?
Procter & Gamble Health Limited reported trailing-twelve-month revenue of about ₹14.1B (latest available figure, as of Sep 13, 2026).
Does Procter & Gamble Health Limited pay a dividend?
Procter & Gamble Health Limited currently shows a dividend yield of about 3.79% relative to its recent price (as of Sep 13, 2026).
What growth is priced into Procter & Gamble Health Limited (PGHL)?
For today's price to be fair in a discounted-cash-flow model, Procter & Gamble Health Limited would have to grow free cash flow by +22.0 % per year for five years (discount rate 12.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +4.1 % per year. As of Sep 13, 2026.
What discount rate (WACC) does the fair value of PGHL use?
Our models discount Procter & Gamble Health Limited at 12.4 %: a base by market capitalisation (small), damped by beta 0.24, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Procter & Gamble Health Limited that is +22.0 % per year a year over ten years, using the same discount rate (12.4 %) and the same formula as our fair value.
How much growth has Procter & Gamble Health Limited (PGHL) delivered so far?
Over the past 5 years revenue at Procter & Gamble Health Limited grew +4.1 % a year. The price currently implies +22.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Procter & Gamble Health Limited (PGHL) growing?
The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into Procter & Gamble Health Limited (+22.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Procter & Gamble Health Limited (PGHL)?
The free-cash-flow yield on the price is 3.59 %: that much free cash flow Procter & Gamble Health Limited produces per unit of market value. When it exceeds the discount rate of our models (12.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Procter & Gamble Health Limited (PGHL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Procter & Gamble Health Limited it is ₹5,073 per share (as of Sep 13, 2026), against a price of ₹5,412. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Procter & Gamble Health Limited stock overvalued or undervalued in 2026?
As of Sep 13, 2026, PGHL trades above its calculated fair value: price ₹5,412, fair value ₹5,073, a gap of about −6% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PGHL?
No. The price is what the market pays today (₹5,412); the fair value is what the company's own numbers justify (₹5,073). For Procter & Gamble Health Limited the two are ₹338.94 per share apart. That gap is exactly why we show both numbers side by side.
How much is Procter & Gamble Health Limited worth?
The market values Procter & Gamble Health Limited at about ₹106B (market capitalisation, as of Sep 13, 2026). Per share that is ₹5,412; our models calculate a fair value of ₹5,073 per share.
What do the bullish and bearish scenarios say about PGHL?
Our models span a range for Procter & Gamble Health Limited: cautious scenario ₹3,280, base ₹5,073, optimistic ₹7,064 per share (as of Sep 13, 2026, price ₹5,412). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of PGHL?
Procter & Gamble Health Limited trades at a price-to-earnings ratio of 27.5 (as of Sep 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹5,073 is built from several models across several years. Other multiples: P/B 20.3, P/S 7.5, EV/EBITDA 22.9.
How solid is the balance sheet of Procter & Gamble Health Limited (PGHL)?
Balance-sheet figures for Procter & Gamble Health Limited (as of Sep 13, 2026): return on equity 61.6%, debt of 0.01 per unit of equity. They feed the Quality Score of 93/100, which measures business quality independently of the share price.
How far is PGHL from its 52-week high?
Procter & Gamble Health Limited trades at ₹5,412, about 19% below its 52-week high of ₹6,700 and 15% above the low of ₹4,707 (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of ₹5,073 is for.
Which stocks are comparable to Procter & Gamble Health Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Procter & Gamble Health Limited stock attractive at the current price?
The data as of Sep 13, 2026: price ₹5,412, calculated fair value ₹5,073 (−6%), Quality Score 93/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PGHL calculated?
We run Procter & Gamble Health Limited through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹5,073, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. Procter & Gamble Health Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with Procter & Gamble Health Limited right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (₹3,280 to ₹7,064) leaves room in how you read the outcome.
Where does the earnings growth of Procter & Gamble Health Limited (PGHL) come from?
Earnings per share at Procter & Gamble Health Limited grew +18.0 % a year from 2014 to 2025. Broken into its drivers: revenue per share +3.4 %, EBIT margin +3.5 %, tax rate +1.2 %, residual (interest, one-offs) +9.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Procter & Gamble Health Limited
How large is the market capitalisation of Procter & Gamble Health Limited (PGHL)?
The market capitalisation of Procter & Gamble Health Limited is ₹106B (≈ $1.1B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Procter & Gamble Health Limited (PGHL)?
The price-to-sales ratio of Procter & Gamble Health Limited is 6.37 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Procter & Gamble Health Limited (PGHL)?
Earnings per share at Procter & Gamble Health Limited are ₹197.12 (price ÷ EPS = P/E 27.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Procter & Gamble Health Limited (PGHL)?
The dividend yield of Procter & Gamble Health Limited is 3.8% (payout 104%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Procter & Gamble Health Limited (PGHL)?
The net margin of Procter & Gamble Health Limited is 23.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Procter & Gamble Health Limited (PGHL)?
The return on equity (ROE) of Procter & Gamble Health Limited is 61.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Procter & Gamble Health Limited (PGHL)?
On an EBIT basis the return on assets of Procter & Gamble Health Limited is 60.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Procter & Gamble Health Limited (PGHL)?
The operating margin of Procter & Gamble Health Limited is 34.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Procter & Gamble Health Limited (PGHL)?
Revenue at Procter & Gamble Health Limited is growing +19.1% versus a year earlier (3y avg +4.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Procter & Gamble Health Limited (PGHL)?
Earnings per share at Procter & Gamble Health Limited are growing +54.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Procter & Gamble Health Limited (PGHL) hold?
Procter & Gamble Health Limited holds more cash than debt, ₹1.8B net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Procter & Gamble Health Limited in the live analysis
One click puts Procter & Gamble Health Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
